ArticleFrontiers in public health2020
Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Methodologies for generating and evaluating clinical and performance evidence for high-risk and innovative medical devices andFrontiers in medical technology · 2026Pooled it
- A systematic review of health economic evaluation quality assessment instruments for medical devices.International journal of technology assessment in health care · 2025Pooled it
- Domains and Methods of Medical Device Technology Evaluation: A Systematic Review.Public health reviews · 2024Pooled it
- Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.PharmacoEconomics · 2026Review
- Ethical Considerations in Health Technology Assessment for Precision Medicine: A Delphi Study in a Greek Setting.Journal of personalized medicine · 2026Article
- Building capacity for medical device assessment: online training for Ukrainian experts.International journal of technology assessment in health care · 2026Article
- Comparison of somatic development, nutritional status, control of disease, and frequency of autoimmune comorbidities in Polish and Ukrainian children with type 1 diabetes.Pediatric endocrinology, diabetes, and metabolism · 2026Article
- Quo Vadis Temporomandibular Disorders? By 2050, the Global Prevalence of TMD May Approach 44.Journal of clinical medicine · 2025Article
- Introducing and utilizing innovative technologies in health care systems: a country comparison for peripheral drug-eluting stents in Germany and the USA.Frontiers in public health · 2025Review
- Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review.Journal of medical Internet research · 2024Article
- Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making.Journal of comparative effectiveness research · 2023Review
- Health technology assessment of medical devices: current landscape, challenges, and a way forward.Cost effectiveness and resource allocation : C/E · 2022Review
- Patent "Evergreening" of Medicine-Device Combination Products: A Global Perspective.Healthcare policy = Politiques de sante · 2022Article
- Coverage with evidence development for medical devices in Europe: Can practice meet theory?Health economics · 2022Article
- Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.Health economics · 2022Article
- Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries.Antibiotics (Basel, Switzerland) · 2022Article
- Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 12 countries.
Rita Daubner-BendesSyreon Research Institute, Budapest, Hungary.
Sándor KovácsSyreon Research Institute, Budapest, Hungary.
Maciej NiewadaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
Mirjana HuicHTA/EBM Consulting Centre, Zagreb, Croatia.
Michael DrummondCentre for Health Economics, University of York, York, United Kingdom.
Oriana CianiCentre for Research on Health and Social Care Management, SDA Bocconi School of Management, Milan, Italy.
Carl Rudolf BlankartKPM Center for Public Management, University of Bern, Bern, Switzerland.
Olena MandrikSchool of Health and Related Research, Health Economics and Decision Science, The University of Sheffield, Sheffield, United Kingdom.
Aleksandra TorbicaCentre for Research on Health and Social Care Management, SDA Bocconi School of Management, Milan, Italy.
John YfantopoulosSchool of Economics and Political Science, University of Athens, Athens, Greece.
Guenka PetrovaDepartment of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Malwina Holownia-VoloskovaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
Rod S TaylorEvidence Synthesis and Modelling for Health Improvement, College of Medicine and Health, Institute of Health Research, University of Exeter, Exeter, United Kingdom.
Maiwenn AlErasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Oresta PiniazhkoHTA Department of State Expert Centre of Ministry of Health of Ukraine, Kyiv, Ukraine.
László LorenzoviciG. E. Palade University of Medicine, Pharmacy, Science and Technology, Tirgu Mures, Romania.
Rosanna TarriconeCentre for Research on Health and Social Care Management, SDA Bocconi School of Management, Milan, Italy.
Antal ZemplényiSyreon Research Institute, Budapest, Hungary.
Zoltán KalóSyreon Research Institute, Budapest, Hungary.
Bocconi University · ITMedical University of Warsaw · PLSyreon Research Institute (Hungary)Croatian National Bank · HRErasmus University Rotterdam · NLMedical University of Sofia · BGMinistry of Health · UAMRC/CSO Social and Public Health Sciences Unit · GBNational and Kapodistrian University of Athens · GRSemmelweis University · HUUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversity of Bern · CHUniversity of Pecs · HUUniversity of Sheffield · GBUniversity of York · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Technology Assessment, BiomedicalCost-Benefit AnalysisEuropeEurope, EasternCentral-Eastern Europe (CEE)health technology assessement (HTA)medical device (MD)methodological challengereal world evidence (RWE)transferabilityvalue assessment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.